MAIA Biotechnology presents THIO-104 and THIO-101 posters at SITC 2025 for NSCLC trials

MAIA Biotechnology, Inc.

THIO-104 Phase 3 study of ategano sine (THIO) sequenced with ICI vs SOC chemo in ICI-resistant advanced NSCLC presented Nov 7.
THIO-101 Phase 2 study of THIO combined with ICI in advanced NSCLC resistant to prior ICI and chemo presented Nov 10.
Posters are in-progress trial updates and contain forward-looking statements; detailed results not disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.